Literature DB >> 21170535

[Update from the soft tissue tumour registry in Jena].

I Petersen1, B Günther, K Mildner, F Subhi, T Knösel, A Altendorf-Hofmann, D Katenkamp.   

Abstract

The Jena Institute of Pathology has been serving as a consultation and reference center for soft tissue tumors in Germany since 1978. The present study provides an overview of the clinicopathological data from a two-year period and an update on diagnostics and research. Retrospectively, 7043 cases sent to the institute in the years 2006 and 2007 were analyzed. The majority of cases (>77.7%) were soft tissue tumors, of which 49% were categorized as malignant, 11.4% as intermediate, 35% as benign and 4.6% as tumors of uncertain biological potential. Neoplasms with fibroblastic differentiation were the most frequent. The mean age of patients with a sarcoma was 63 years. The molecular pathological analysis of soft tissue tumors has attained a major role in diagnosis. This is further advanced at the Jena institute in the context of a German Federal Ministry of Education and Research (BMBF) project for molecular sarcoma diagnosis with the aim of developing and validating DNA probes for in situ hybridization detection of translocations and their associated chromosomal breaks on the one hand, and DNA chips for the detection of fusion transcripts on the other. Research projects relate to the analysis of specific biomarkers in large tumor collectives and the pathomechanisms in several sarcoma entities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21170535     DOI: 10.1007/s00292-010-1399-6

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  20 in total

1.  TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.

Authors:  Jefferson Terry; Tsuyoshi Saito; Subbaya Subramanian; Cindy Ruttan; Cristina R Antonescu; John R Goldblum; Erinn Downs-Kelly; Christopher L Corless; Brian P Rubin; Matt van de Rijn; Marc Ladanyi; Torsten O Nielsen
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

Authors:  Marc Ladanyi; Cristina R Antonescu; Denis H Leung; James M Woodruff; Akira Kawai; John H Healey; Murray F Brennan; Julia A Bridge; James R Neff; Frederic G Barr; Jeffrey D Goldsmith; John S J Brooks; John R Goldblum; Syed Z Ali; Janet Shipley; Colin S Cooper; Cyril Fisher; Björn Skytting; Olle Larsson
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

4.  SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.

Authors:  A Kawai; J Woodruff; J H Healey; M F Brennan; C R Antonescu; M Ladanyi
Journal:  N Engl J Med       Date:  1998-01-15       Impact factor: 91.245

5.  The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.

Authors:  C Filion; T Motoi; A B Olshen; M Laé; R J Emnett; D H Gutmann; A Perry; M Ladanyi; Y Labelle
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

6.  Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan.

Authors:  Satoshi Takenaka; Takafumi Ueda; Norifumi Naka; Nobuhito Araki; Nobuyuki Hashimoto; Akira Myoui; Toshifumi Ozaki; Tomitaka Nakayama; Junya Toguchida; Kazuhiro Tanaka; Yukihide Iwamoto; Akihiko Matsumine; Atsumasa Uchida; Makoto Ieguchi; Mitsunori Kaya; Takuro Wada; Ichiro Baba; Ikuo Kudawara; Yasuaki Aoki; Hideki Yoshikawa
Journal:  Oncol Rep       Date:  2008-02       Impact factor: 3.906

Review 7.  [HPV in non-gynecological tumors].

Authors:  I Petersen; F Klein
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 8.  Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.

Authors:  Eva Wardelmann; Reinhard Büttner; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus
Journal:  Virchows Arch       Date:  2007-08-14       Impact factor: 4.064

Review 9.  Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET.

Authors:  N Riggi; L Cironi; M-L Suvà; I Stamenkovic
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

10.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

Authors:  Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

View more
  2 in total

1.  Thoracic neoplasms at the Jena reference center for soft tissue tumors.

Authors:  Kathrin Nitsche; Bianka Günther; Detlef Katenkamp; Iver Petersen
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-09       Impact factor: 4.553

Review 2.  [The new WHO classification and recent results in soft tissue tumor pathology].

Authors:  I Petersen
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.